Introduction {#sec1-1}
============

Inflammatory bowel diseases (IBD) are a group of chronic relapsing disorders of the gastrointestinal tract whose major types are ulcerative colitis (UC) and Crohn\'s disease (CD). The incidence of these disorders in Europe has increased during the last 50 years \[[@ref1]\]: for UC from 6.0 per 100,000 person-years to 9.8 per 100,000 person-years and for CD from 1.0 per 100,000 person-years to 6.3 per 100,000 person-years \[[@ref1]\].

Although IBD seems to represent a result of a dysregulated host--microbe interaction in genetically susceptible individuals, its etiology has not been sufficiently established \[[@ref2]\]. Several risk factors have been studied, including genetic factors, psychological factors or other environmental factors such as smoking \[[@ref2],[@ref3]\]. Among these, diet is implicated in both the development and the course of IBD. Specifically, a western pattern diet comprising high amounts of fat and sugar and low amounts of fiber has been reported to contribute to the development of IBD \[[@ref2]-[@ref4]\]. In addition, several studies have examined the impact of alcohol consumption on IBD \[[@ref5],[@ref6]\].

Alcohol consumption is well known to be both pro-inflammatory and directly harmful to gut barrier function, as it breaks down the normal physical and immunological barrier provided by intestinal epithelial cells and gut-associated lymphoid tissue, respectively \[[@ref7]\]. Clinical studies have indicated that alcohol consumption may provoke symptoms and/or relapse in an inactive disease \[[@ref8]\]. The potential influence of alcohol use on IBD pathogenesis seems to be greater in adults \[[@ref9]\].

Patients who suffer from CD are prone not only to the complications of a relapsing, unpredictable disease, but also to feelings of stigmatization, depression and increased risk of suicidal ideation, suicide, or drug and alcohol abuse \[[@ref10]\]. Substance abuse and concurrent psychiatric disorders could be associated with several factors in chronic prescription narcotic users \[[@ref11]\]. Furthermore, one of the main symptoms of IBD is abdominal pain; therefore, narcotics are often prescribed for pain relief for short periods.

Pain related to disease activity, complications, or surgeries is often treated with opioid analgesics. Because of concerns about risks or side effects of medications, many patients have an interest in alternative therapies, alone or as a supplement to standard treatment protocols \[[@ref12]\]. A significant positive relationship has been reported between the use of narcotic analgesics and the development of serious infections in CD patients \[[@ref13]\]. However, because of the chronic course of the disease, the number of flares, or comorbidities such as anxiety or depression, many patients end up using these drugs for longer periods than originally planned \[[@ref14],[@ref15]\]. Narcotic use has not been shown to be effective in the management of CD, but patients with CD have been found to have fairly high rates of chronic prescription narcotic use \[[@ref16]\].

The aim of this review was to gather the available evidence on the role of alcohol in the development and course of IBD as well as the prevalence of narcotics use among non-hospitalized IBD patients.

Materials and methods {#sec1-2}
=====================

We conducted a comprehensive literature review of the Medline database from inception through to March 2016. We utilized the Boolean search operators "AND" and "OR", the PubMed Advanced Search Builder and the relevant search filters. The following keywords were used in our search: inflammatory bowel disease, Crohn\'s disease, ulcerative colitis, alcohol, wine, beer, drug abuse, narcotics, opioid. The references of the retrieved articles were searched manually to identify additional studies.

We included only English-language studies that investigated the use of alcohol or narcotics among IBD patients. In the case of narcotics, we included only studies that examined their use as analgesics for IBD-related pain. We excluded studies that did not provide any relevant information, those that included only hospitalized patients, as well as studies whose full text we were not able to retrieve through our library.

The details of the research items, with reference to Participants, Interventions, Comparisons, Outcomes, and Study design (PICOS/PRISMA) \[[@ref17]\] are presented in [Fig. 1](#F1){ref-type="fig"} and in detail in [Fig. 2](#F2){ref-type="fig"}. Twelve studies were identified that examined the use of alcohol among IBD patients \[[@ref5],[@ref6],[@ref18]-[@ref27]\] and 4 that examined narcotics use \[[@ref14],[@ref15],[@ref28],[@ref29]\]. Of the studies examining alcohol use, 3 provided data on the prevalence of alcohol use \[[@ref18]-[@ref20]\], 1 investigated the association between alcohol use and the development of IBD \[[@ref21]\], and 8 examined the impact of alcohol consumption on IBD symptoms \[[@ref5],[@ref6],[@ref22]-[@ref26]\].

![Flowchart of the search strategy](AnnGastroenterol-31-649-g001){#F1}

![Search strategy in details](AnnGastroenterol-31-649-g002){#F2}

According to some studies, moderate alcohol consumption is defined as having up to 1 drink per day for women and up to 2 drinks per day for men. This definition refers to the amount consumed on any single day and is not intended as an average over several days \[[@ref30]\]. Studies included in our research present heterogeneity, but this definition is in any case difficult to process.

Results {#sec1-3}
=======

Alcohol use and the development of IBD {#sec2-1}
--------------------------------------

Two studies were conducted in Copenhagen in order to determine whether patients with UC or CD differed significantly in terms of various parameters, including alcohol consumption, compared to controls. In the first study, the researchers interviewed 122 UC patients attending an outpatient gastroenterology clinic and 83 sex- and age-matched controls admitted to the same hospital for various other reasons. They collected data on patients' social and professional status, as well as daily alcohol intake, and they reported that the daily alcohol consumption was equal in both groups \[[@ref18]\]. Likewise, another study enrolled 106 CD patients and 75 controls and performed personal interviews about the patients' and controls' family, social and professional conditions, as well as alcohol intake. The majority of CD patients reported that they did not drink alcohol (74%), 24% of them drank up to 5 glasses of alcohol per day, whereas only 2% drank more than 5 glasses per day. Similarly, 79% of the controls reported that they did not drink, while only a small percentage (4%) drank more than 5 glasses per day. The results showed that alcohol intake did not differ between CD patients and controls \[[@ref19]\].

The prevalence of alcohol use was studied among 403 patients aged 9-18 years with chronic conditions through the completion of a self-administered questionnaire. Almost one third of all participants (30.8%) reported past-year alcohol use, whereas older age was positively associated with alcohol use. It should be noted that, among all participants, 53.1% were aware of the fact that alcohol can interfere with medications and 37.2% that alcohol can interfere with laboratory tests. The results showed that a total of 100 patients had IBD and 39.5% reported past-year alcohol use, and approximately half (46.9%) reported binge drinking \[[@ref20]\].

Possible risk factors for the development of UC were investigated in a Chinese population. In this study, 177 UC patients and 177 controls, either neighbors or colleagues of the patients, completed a structured questionnaire regarding various risk factors. Alcohol drinking was classified as frequent when the individuals drank on 3 or more days per week, light when they drank on fewer than 3 days per week, and non-drinking when they never or rarely drank. A protective effect against the development of UC was reported for light drinking compared with never drinking (odds ratio \[OR\] 0.52, 95% confidence interval \[CI\] 0.32-0.85, P=0.009), however this protective effect was not confirmed by the multivariate analysis of risk factors \[[@ref21]\].

The studies that examined the impact of alcohol consumption on IBD symptoms are presented in [Table 1](#T1){ref-type="table"}. The association of dietary factors and the likelihood of relapse among UC patients was studied among 183 participants who were asked to complete a food frequency questionnaire and the clinical colitis activity index to determine relapse or remission of the disease. High alcohol intake was associated with a higher frequency of reported relapses (OR 2.71; 95%CI 1.10-6.67). The median daily consumption of alcoholic beverages reported by the group of patients with frequent relapses was 238 g, whereas in the non-relapse group of patients the daily consumption was 150 g. The authors also found an association between relapses and a high intake of sulfite (OR 2.61; 95%CI 1.08-6.30), an additive commonly found in processed foods as well as alcoholic beverages \[[@ref22]\].

###### 

Characteristics of the studies evaluating the impact of alcohol consumption on symptoms among patients with IBD (n=8)
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The impact of diet on disease activity among 81 UC patients was examined by a study in which all participants completed a 7-day diet diary, after which they underwent a clinical assessment of disease activity, including a sigmoidoscopic examination, and were assigned clinical scores \[[@ref23]\]. In order to estimate the impact of diet on clinical scores the investigators developed a Food Sigmoidoscopy Score (FSS). A higher FSS was associated with high consumption of each particular food examined in the study and high levels of disease activity. The consumption of red wine and beer was positively correlated with the sigmoidoscopy scores (*r*^2^=0.07, P\<0.02). Red wine, white wine, bitter and lager were associated with higher FSS (Mann-Whitney, P\<0.001). All these alcoholic beverages had in common the fact that they contain sulfite. On the other hand, spirits, which do not contain sulfite, were not associated with UC disease activity. Therefore, the authors suggested that sulfite, rather than alcohol, was affecting UC disease activity \[[@ref5]\].

The CD patients' perspectives on the factors that may be associated with their symptoms was examined in a study in which 1220 CD patients participated. The majority of CD patients who consumed alcohol preferred beer (43%), wine (36%), liquors (44.8%), or mixed drinks (41%). Interestingly, 4 of 10 reported that alcohol worsened their symptoms, whereas the same proportion reported that alcohol consumption did not have an impact on their symptoms. When the different alcoholic beverages were compared, their association with the worsening of symptoms showed no significant variation \[[@ref23]\]. A similar study tried to evaluate the impact of 5 different alcoholic beverages on gastrointestinal symptoms and disease activity when given to fasting CD patients in remission \[[@ref24]\]. For this purpose they recruited 20 CD patients in remission (Crohn\'s Disease Activity Index score \<150) and 20 healthy controls, all of whom underwent 6-h fast and were not allowed to consume alcohol for 48 h prior to the investigation. The participants were randomly given either 36 g (men) or 24 g (women) of 5 different alcoholic drinks (red wine, white wine, Smirnoff Ice, Elephant Beer, or pure ethanol). They then underwent consecutive blood sampling up to 3 h after alcohol consumption, to assess serum ethanol and plasma glucose concentrations, and they also reported abdominal pain symptom scores at each time. No difference was observed in ethanol concentration between patients and controls, whereas plasma glucose levels were significantly higher (P\<0.05) among CD patients who consumed either Smirnoff Ice or Elephant Beer. Interestingly, the CD patients who consumed the aforementioned high-sugar drinks reported more pronounced abdominal pain compared to those who consumed pure ethanol (P\<0.05); however, no increase in disease activity index was reported \[[@ref24]\].

The role of the quantity of alcohol consumption in IBD symptoms and the self-reported effects were investigated in a study of 129 UC, CD, and irritable bowel syndrome (IBS) patients. All IBD patients included in the study had biopsy-proven CD or UC. IBS patients had to meet the Rome II criteria for IBS, and had a normal colonoscopy. The authors followed the National Institute of Alcohol Abuse and Alcoholism (NIAAA) to classify the patients into abstainers (\<12 drinks per year), current drinkers (\>12 drinks per year), light drinkers (≤3 drinks per week), moderate drinkers (\>3 to ≤14 drinks per week), heavy drinkers (\>14 drinks per week), and binge drinkers (\>5 drinks on one occasion). More than half of the CD and UC patients were current drinkers. Among these, 21% of CD patients and 26% of UC patients were light drinkers, whereas 33% and 24%, respectively, were moderate drinkers. The authors noted that alcohol consumption patterns among IBD patients were similar to those of the general population. The majority of CD and UC patients who were current drinkers reported worsening of their symptoms with alcohol consumption, whereas this did not apply to the IBS patients. IBD patients with upper gastrointestinal symptoms consumed less alcohol than IBD patients without these symptoms. However, no statistical association was reported between the severity of the symptoms and the quantity of alcohol consumed, while the type of alcoholic beverage also did not appear to play a role \[[@ref6]\].

A similar study attempted to evaluate the dietary tolerances and intolerances of 446 CD patients. All participants were asked to complete a food tolerance questionnaire, which included 257 food items, by scoring the items on a 5-point scale. Items with the most negative numbers were considered as the least beneficial. More than half of the responders reported that beer, red wine and champagne increased the adverse effects. Four of 5 reported that the consumption of white wine had an adverse effect on their symptoms. Only a small percentage of the participants reported that alcoholic beverages were well tolerated, with red wine having a beneficial effect on almost 5% of CD patients \[[@ref25]\]. Another study aimed to evaluate the effects of moderate alcohol drinking on markers of disease activity in inactive IBD, namely stool calprotectin and intestinal permeability. The researchers recruited 23 IBD patients, all social drinkers, in clinical remission and asked them to complete questionnaires regarding alcohol consumption and disease activity. Upon enrollment the participants were asked to refrain from drinking alcohol for a period of 1 week, after which blood, stool and urine samples were collected as baseline assessment from the IBD patients and from 7 healthy controls. The patients were then instructed to drink 1-3 glasses of red wine per day for a period of 1 week, after which they underwent repeat examinations. None of the participants reported worsening of their symptoms and the clinical activity indexes before and after the alcohol consumption did not differ. Stool calprotectin was significantly decreased compared to baseline after 1 week of alcohol consumption in IBD patients (P=0.001). Markers of intestinal permeability were similar among IBD patients and controls at baseline. Wine consumption significantly affected these markers in IBD patients: namely, urinary lactulose/mannitol excretion was increased in CD patients (P=0.028) and urinary sucralose secretion was increased in UC patients (P=0.012) \[[@ref26]\].

Finally, Cohen *et al* utilized the cohort of an internet-based study and included 6768 patients in their study. All participants completed a survey that included a food frequency questionnaire originally developed by the National Cancer Institute, as well as open-ended questions regarding the patients' perceptions of the impact of food items on their symptoms. Alcohol was found to significantly worsen symptoms among CD patients without ostomy or pouch, UC patients without ostomy and pouch, as well as UC patients with a pouch (P\<0.01) \[[@ref27]\].

Narcotics use among IBD patients {#sec2-2}
--------------------------------

The studies that examined the narcotics use among IBD patients are presented in [Table 2](#T2){ref-type="table"}. The diagnostic and statistical manual of mental disorders was used to establish a psychiatric diagnosis of 1500 participants in a study of IBD patients. Based on this analysis, 30.2% of these patients were found to meet the criteria for drug dependence. The most common source of drug dependence was iatrogenic and dependence was observed an average of 7.4 years after the diagnosis of IBD. In addition, 38% of the patients who were drug dependent were also diagnosed with a borderline personality disorder, compared with 7% of the patients who were not drug dependent \[[@ref14]\].

###### 

Characteristics of the studies evaluating the narcotics use among patients with inflammatory bowel disease (IBD) (n=4)
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In a similar study, the authors utilized a large IBD database to evaluate the prevalence of chronic narcotic use among 332 IBD patients and they defined chronic narcotic use as either the continuous use of oral codeine (\>300 mg/week) for abdominal pain, or frequent intermittent narcotic use (morphine, pethidine, physeptone) over a period of at least 6 months. They reported that 2.7% of all IBD patients, 5.1% of CD patients and 1 UC patient were chronic narcotics users. CD patients who used narcotics had been diagnosed with CD for an average of 15 years. It is notable that no evidence of disease flare-ups was found among IBD patients using narcotics over the period of the study. IBD narcotic users were more likely to have been diagnosed at some time with a comorbid psychiatric disorder, or to have had a psychiatric diagnosis prior to the IBD diagnosis, than IBD patients not using narcotics (OR 22, 95%CI 3.24-177, P=0.002; and OR 9.6, 95%CI 1.36-67, P=0.045, respectively) \[[@ref28]\].

Another study of narcotics use in IBD patients was carried out in a specialized IBD clinic and the researchers tried to assess the disease activity, the self-reported prevalence of opioid analgesic use among the patients, and its association with the health-related quality of life (HRQoL). They also used the Harvey Bradshaw Index (HBI) and the inflammatory bowel disease questionnaire (IBDQ) to evaluate the disease activity and the HRQoL, respectively. Thirty-eight IBD patients used opioids and there were several differences between opioid users and non-opioid users. Among opioid users the average duration of disease was significantly longer, the number of hospital admissions was greater, the number of surgeries was greater and the use of prednisone was more frequent compared to non-opioid users (18.5 vs. 9 years, P=0.005; median 5 vs. 1, P\<0.001; median 3 vs. 0, P\<0.001; and 29% vs. 11.3%, P=0.03, respectively). Furthermore, opioid users had more active disease and impaired HRQoL as compared to non-opioid users (HBI score 9 vs. 3, P\<0.01; IBDQ score 109.3 vs. 162.9, P\<0.001). Higher daily opioid use was associated with lower HRQoL (*r*=-0.58, P\<0.001). IBD patients using more than 50 mg daily of oral morphine had significantly impaired HRQoL as compared to those using less than 50 mg (IBDQ score 99.3 vs. 116.6, P=0.001) \[[@ref29]\].

Finally, Buckley *et al*, using an administrative claims database, investigated narcotics use among the pediatric IBD population (aged 0-18 years old). A total of 4334 children with IBD and 21720 randomly sampled healthy controls were included in the study. The authors used prescription drug claims to establish narcotics use and defined participants who had 3 or more narcotic drug claims during a 2-year period as chronic users. They reported that 5.6% of IBD children were chronic narcotics users and that this population had twice the prevalence odds ratio (POR) of narcotic use as compared with controls (POR 2.59, 95%CI 2.21-3.04). Furthermore, chronic narcotics use and IBD status were significantly more strongly associated among younger children with IBD (aged 0-9 years old) and children with IBD and a comorbid mental health problem (anxiety, depression, use of relevant medications or any psychological impairment) \[[@ref15]\]. Older age, male sex, the presence of any psychological impairment, oral steroid use and a greater number of outpatient visits were among the factors associated with higher chronic narcotics use among children with IBD (POR 3.06, 95%CI 1.61-5.84; POR 1.02, 95%CI 0.76-1.37; POR 2.72, 95%CI 2.02-3.67; POR 1.00, 95%CI 0.73-1.35; and POR 1.87, 95%CI 1.20-2.91, respectively) \[[@ref18]\].

Discussion {#sec1-4}
==========

Several possible mechanisms have been suggested through which alcohol consumption may impact on IBD symptoms. It has been reported that alcohol consumption could affect the luminal immune system by increasing intestinal permeability and antigen exposure. Furthermore, the high sugar content of alcoholic beverages can cause an osmotic diarrhea \[[@ref6],[@ref30],[@ref31]\]. Research has shown that IBD patients and alcoholic patients carry an intestinal bacterial dysbiosis \[[@ref32]-[@ref36]\]. A dysbiosis is believed to provide pathogens an opportunity to colonize and proliferate. Indeed, studies have shown IBD patients and alcoholics are at risk for increased infections \[[@ref37]\].

Regarding alcohol, the prevalence of its consumption among IBD patients seems to be similar to that of the general population, whereas increased prevalence has been reported among children with IBD \[[@ref18]-[@ref20]\]. Even though light alcohol consumption has been reported by one study as a potential protective factor against the development of IBD, the majority of studies examining the impact of alcohol on IBD abdominal symptoms and disease activity reported deleterious effects \[[@ref5],[@ref6],[@ref22]-[@ref25],[@ref27]\]. Although studies failed to identify a single specific alcoholic beverage or quantity with the greatest impact on IBD symptoms \[[@ref6],[@ref23]\] some studies reported that other ingredients of alcoholic drinks rather than alcohol itself may play a role. Specifically, 2 studies concluded that high intake of sulfite, an additive commonly used in alcohol drinks, was associated with a higher risk of relapses and increased disease activity \[[@ref5],[@ref22]\], whereas one study reported that the consumption of alcoholic drinks that contain more sugars is associated with a greater prevalence of abdominal pain \[[@ref24]\]. It should be noted, however, that the majority of studies made no objective measurements of the impact of alcohol on IBD symptoms; most of the symptoms were self-reported and therefore subjective.

Abdominal pain is a common and debilitating symptom among IBD patients \[[@ref38]\]. In the past, narcotics were often contraindicated in patients with IBD for fear of precipitating toxic megacolon, but nowadays narcotics are commonly used in the IBD population \[[@ref39]\]. Development of chronic abdominal pain is an under-recognized side effect of opioid use. Narcotic bowel syndrome, which occurs in a small proportion of chronic opioid users, consists of chronic or intermittent abdominal pain \[[@ref40]\].

Narcotics use appears to be a significant factor that can complicate IBD, as a significant portion of IBD patients using narcotics meet the criteria for drug dependence, while it has also been reported that treatment with narcotics can significantly predict death among IBD patients \[[@ref13],[@ref14]\]. It is estimated that approximately 5-13% of patients with IBD are on chronic narcotics in the outpatient setting \[[@ref16]\]. Patients may also turn to narcotics, either as an alternative to normal therapy, because of concerns about the risks of medications, or as a supplement to standard treatment protocols \[[@ref41]\]. Some studies suggest that patients with IBD who use marijuana can derive symptomatic benefits \[[@ref42]\]. Cannabis use also provides symptom relief in patients with IBD, but is associated with a worse disease prognosis in patients with CD, while exogenous cannabinoids can also reduce colitis \[[@ref43]\]. Furthermore, through mechanisms such as stimulating antikinetic neurotransmitters, promoting dysmotility and injuring enteric neurons narcotics are associated with colonic pseudo-obstruction \[[@ref44]\].

From the available studies it was evident that the use of narcotics for analgesia is prevalent among adult and young IBD patients and is associated with more active disease and impaired quality of life Furthermore, it is reported that psychological dysfunction is one of the factors contributing to pain perception by IBD patients \[[@ref27]\]. Notably, all the included studies in the present review reported that, among IBD patients, those with a longer duration of disease and those with comorbid mental health illnesses were more likely to be narcotics users \[[@ref14],[@ref15],[@ref28],[@ref29]\].

Interestingly, the majority of the studies examining alcohol consumption and also narcotic use among IBD patients adjusted their results according to the patients' age and sex---without, however, taking ethnic or cultural differences into account. It is reported that the prevalence of alcohol and drugs use varies between different ethnic populations \[[@ref45]\]. Therefore, future studies acknowledging this factor are needed.

In conclusion, overall, IBD is a multi-faceted chronic disease and as such it requires continuous vigilance and research into all its aspects. From the available literature data, it was evident that alcohol consumption among IBD patients may be associated with worsening of their symptoms, whereas a high proportion of IBD patients use narcotics to relieve their pain. Regarding alcohol, more studies are needed to establish its exact role in IBD, or perhaps to evaluate whether there is a potential specific quantity that IBD patients may safely consume. Concerning narcotics, the reasons for and the patterns of their increased use among IBD patients should be further assessed to address this very important issue.
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